Our findings highlight that disruption of SNRPD3 protein methylation using PRMT5 inhibitors is a promising novel therapeutic target for the treatment of high-risk neuroblastoma, particularly given the observed SNRPD3- and MYCN-selectivity. This evidence concerns the gene MYCN and neuroblastoma.